2.4 Mantle Cell Lymphoma (MCL)
Most patients with MCL respond well to treatment and have an excellent
prognosis. However, as with most other B-cell lymphomas, MCL patients
are highly heterogeneous and have a different proportion of different
genes and mutation types in the tumor. Up to 84% of the cyclin D1
(CDC10) gene rearrangement in tumors of MCL patients occurs in one or
more B-cell lymphomas.